Suggested remit: To appraise the clinical and cost effectiveness of sodium thiosulfate within its marketing authorisation for preventing ototoxicity in people aged 1 month to 17 years old with localised cancer having cisplatin chemotherapy.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 1001

Provisional Schedule

Committee meeting: 1 11 September 2024

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Fennec Pharmaceuticals
Others Great Ormond Street Hospital (London)
  Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups Auditory Verbal UK
  Black Health Agency for Equality
  British Deaf Association
  Cancer Black Care
  Cancer Equality
  Catholic Deaf Association
  Childhood Cancer Parents Alliance
  Children with Cancer
  Christian Deaf Link UK
  Cochlear Implanted Children’s Support Group
  Deafblind UK
  Hearing LINK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Meniere’s Society
  National Association of Deafened People
  National Cochlear Implant Users Association
  National Deaf Children’s Society
  Royal Association for Deaf People
  Royal National Institute for Deaf People
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Teenage Cancer Trust
  Tenovus Cancer Care
  Young Lives vs Cancer
  UK Council on Deafness
Professional groups Association of Cancer Physicians
  British Academy of Audiology
  British Association of Audiological Physicians
  British Association of Educational Audiologists
  British Association of Otolaryngologists, Head & Neck Surgeons
  British Association of Paediatricians in Audiology
  British Association of Teachers of the Deaf
  British Cochlear Implant Group
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society of Audiology
  British Society of Hearing Aid Audiologists
  Cancer Research UK
  Chartered Society of Physiotherapy
  Children’s Cancer & Leukaemia Group
  Neonatal and Paediatric Pharmacists Group
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Speech and Language Therapists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  Vestibular Interdisciplinary Working Group (VIWG)
Associated guideline groups NICE - National Guideline Alliance
Associated public health groups Public Health Wales
  UK Health Security Agency
Evidence review group School of Health and Related Research (ScHARR)
  National Institute for Health Research Health Technology Assessment Programme (NETSCC)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Action on Hearing Loss
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
13 February 2024 Invitation to participate
07 February 2024 Topic selection
07 February 2024 The topic was considered by the Topic Selection Oversight Panel (TSOP) in January 2024. The panel concluded that a routing to the Technology Appraisal (TA) programme is appropriate for this topic.
28 November 2023 - 05 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1001
28 November 2023 In progress. Scoping commenced.
27 October 2023 Please note that following on from a request received from the company, the timelines for this evaluation have been revised and the evaluation is now anticipated to begin during mid-February 2024 when we will write to you about how you can get involved.
22 January 2021 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of sodium thiosulfate within its marketing authorisation for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy. Please note that following advice received from the company the timelines for this appraisal are to be confirmed. We hope to have a further update for you in due course.
22 January 2021 In progress. Topic is in progress
11 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
23 January 2020 - 20 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual